Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
← catalyst calendarSponsored by Genfit (industry) · GNFT.PA — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
52actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-26 | actual | When the study began enrolling |
| Primary completion | 2025-12-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-03 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute-on-Chronic Liver Failure
Interventions
- Drug: Single Dose G1090N
- Drug: Multiple dosing of G1090N
Primary outcomes
what the primary-completion date above is the date OFMaximum Concentration (Cmax)
measured Up to Day 9
Time to Cmax (tmax)
measured Up to Day 9
Area under the plasma concentration-time curve (AUC)
measured Up to Day 9
Terminal half-life (t1/2)
measured Up to Day 9
Amount excreted (Ae)
measured Up to Day 8
Renal clearance (CLr)
measured Up to Day 8
Fraction of dose excreted (fe)
measured Up to Day 8
Permalink · GNFT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed